S. Al-Batran

2.1k citations

40 papers · 1.5k indexed · 1 hit paper · h-index 15

Impact in

Gastroenterology top 5%
- Gastrointestinal Tumor Research and Treatment
Oncology top 5%
- Colorectal Cancer Treatments and Studies
- Viral-associated cancers and disorders
- Pancreatic and Hepatic Oncology Research

Papers in

Gastroenterology 8
- Gastrointestinal Tumor Research and Treatment 8
Pulmonary and Respiratory Medicine 26
- Gastric Cancer Management and Outcomes 21
- Lung Cancer Treatments and Mutations 6

Co-authors: Ralf‐Dieter Hofheinz Florian Lordick Elke Jäger Akin Atmaca Claudia Pauligk M. L. Hansmann Dorothea Kofahl-Krause Heinz Dürk
Journals: Journal of Clinical Oncology (17 papers)Annals of Oncology (9 papers)British Journal of Haematology (2 papers)European Journal of Cancer (2 papers)Respiration (1 paper)
Partner nations: Germany United States Belgium

In The Last Decade

S. Al-Batran

36 papers receiving 1.4k citations

Hit Papers

align trajectories log scale

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma 2021 · 244 citations

Peers

Countries citing papers authored by S. Al-Batran

Since Specialization

Citations

This map shows the geographic impact of S. Al-Batran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Al-Batran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Al-Batran more than expected).

Fields of papers citing papers by S. Al-Batran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Al-Batran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Al-Batran. The network helps show where S. Al-Batran may publish in the future.

Co-authorship network

The 25 scholars most cited alongside S. Al-Batran, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with S. Al-Batran Line = papers co-authored together S. Al-Batran links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO European Journal of Cancer ·Sylvie Lorenzen, Peter Thuss‐Patience, Claudia Pauligk, Abdelouahab Mohammed Taifour, Thomas J. Ettrich, Florian Lordick, Michael Stahl, Peter Reichardt, Martin Sökler, Daniel Pink, Глухов А.П., Axel Hinke, Thorsten Oliver Goetze, S. Al-Batran	2022	26
2	FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma Annals of Oncology ·Uğur Şahin, Ö. Türeci, Georgy M. Manikhas, Florian Lordick, Andriy Rusyn, Ihor Vynnychenko, Assen Dudov, I. Bazin, Igor Bondarenko, Bohuslav Melichar, Karl Dhaene, Kai Wiechen, Christoph Huber, Daniel Maurus, Ahsan M. Arozullah, J.W. Park, Martin Schüler, S. Al-Batran Hit paper breakdown →	2021	244
3	Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma The Oncologist ·Daniel V.T. Catenacci, Joseph Chao, Kei Muro, S. Al-Batran, Samuel J. Klempner, Zev A. Wainberg, Manish A. Shah, Sun Young Rha, Atsushi Ohtsu, Astra M. Liepa, Holly Knoderer, Anindya Chatterjee, Eric Van Cutsem	2021	16
4	Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study European Journal of Cancer ·Eric Van Cutsem, Kei Muro, David Cunningham, G. Bodoky, Alberto Sobrero, Stefano Cascinu, Jaffer A. Ajani, Sang Cheul Oh, S. Al-Batran, Zev A. Wainberg, Sameera R. Wijayawardana, Symantha Melemed, D. Ferry, Rebecca R. Hozak, Atsushi Ohtsu	2020	28
5	Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER) Annals of Oncology ·Markus Moehler, Annett Maderer, Peter Thuss‐Patience, Baruch Brenner, Jens Meiler, Thomas J. Ettrich, Ralf‐Dieter Hofheinz, S. Al-Batran, Arndt Vogel, Lothar Mueller, Manfred P. Lutz, Florian Lordick, María Alsina, K Borchert, Richard Greil, Wolfgang Eisterer, Arno Schad, Julia Slotta‐Huspenina, Eric Van Cutsem, Sylvie Lorenzen	2020	66
6	EVITA—a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity Annals of Oncology ·Ralf‐Dieter Hofheinz, Sylvie Lorenzen, Jörg Trojan, Janja Ocvirk, Thomas J. Ettrich, S. Al-Batran, H. Schulz, Nils Homann, سمية ترحمي, Michael Schatz, Melanie Kripp, Nadine Schulte, D. Pinna, S. Heeger, Soetkin Vlassak, Kirsten Merx	2018	15
7	LBA-06 IMAB362: a novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancer Annals of Oncology ·S. Al-Batran, Martin Schüler, Zanete Zvirbule, George Manikhas, F. Lordick, Özlem Türeci, Christoph Huber	2016	7
8	Workload and Quality of Life of Medical Doctors in the Field of Oncology in Germany - a Survey of the Working Group Quality of Life of the AIO for the Study Group of Internal Oncology Oncology Research and Treatment ·Matthias Hipp, Lothar R. Pilz, S. Al-Batran, Matthias Hautmann, Ralf‐Dieter Hofheinz	2015	10
9	Rainbow: Global, Phase 3, Randomized, Double-Blind Study of Ramucirumab Plus Paclitaxel vs Placebo Plus Paclitaxel Patients with Previously Treated Gastric or Gastroesophageal Junction Adenocarcinoma – Patient-Reported Outcomes and Performance Status Annals of Oncology ·S. Al-Batran, Eric Van Cutsem, Victor, G. Bodoky, Yoshifumi Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae Yong Kim, David Cunningham, P. Rougier, Kei Muro, Richard I. Tumin, Sylvia Gallo, Michael Emig, Atsushi Ohtsu, H. Wilke	2014	1
10	Behandlungsalgorithmen für Adenokarzinome des Magens oder ösophagogastralen Übergangs Der Onkologe ·S. Al-Batran, 黄兵, Stefan Mönig	2013	1
11	Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas Annals of Oncology ·Eckhart Weidmann, Antje Neumann, F. Fauth, Akin Atmaca, S. Al-Batran, Claudia Pauligk, Elke Jäger	2011	65
12	Treatment of Epidermal Growth Factor Receptor Antagonist-Induced Skin Rash: Results of a Survey among German Oncologists Onkologie ·Jessica C. Hassel, Melanie Kripp, S. Al-Batran, Ralf‐Dieter Hofheinz	2010	34
13	Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie Annals of Oncology ·Sylvie Lorenzen, Tibor Schuster, Rainer Porschen, S. Al-Batran, Ralf‐Dieter Hofheinz, Peter Thuss‐Patience, Markus Moehler, Patricia Grabowski, Dirk Arnold, Tim F. Greten, Shahrul Nizam Mohammad Nur Amirullah, Nadine Röthling, C. Peschel, Rupert Langer, Florian Lordick	2009	169
14	Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Annals of Oncology ·S. Al-Batran, J. T. Hartmann, Ralf‐Dieter Hofheinz, Nils Homann, Volker Rethwisch, Stephan Probst, Jan Stoehlmacher, Michael Clemens, Rolf Mahlberg, Mary Ann Fritz, G. Seipelt, Mark Sievert, Claudia Pauligk, Akin Atmaca, Elke Jäger	2008	183
15	Cetuximab and cisplatin/5-FU (CF) versus CF in first-line metastatic squamous cell carcinoma of the esophagus (MESCC): A randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Journal of Clinical Oncology ·Florian Lordick, Sylvie Lorenzen, S. Al-Batran, Ralf‐Dieter Hofheinz, Peter Thuss‐Patience, Rainer Porschen, Nadine Röthling, Tibor Schuster, C. Peschel	2008	9
16	The prognostic role of the epidermal growth factor receptor (EGFR) in patients with metastatic gastric cancer receiving first-line chemotherapy: Results from the FLO versus FLP gastric cancer phase III trial of the AIO Journal of Clinical Oncology ·Claudia Pauligk, Ralph M. Wirtz, K. Steinmetz, A Hungarian, J.T. Hartmann, Ralf‐Dieter Hofheinz, Nils Homann, H. Altmannsberger, Christoph Petry, Eliézer Jäger, S. Al-Batran	2008	1
17	Results from a phase I dose escalation study of PEGylated glutaminase in combination with 6-diazo-5-oxo-L-norleucine (DON) in advanced malignant solid tumors Journal of Clinical Oncology ·Clemens Unger, Carolyn Muller, Eliézer Jäger, Stephen L Cole, Justin Roberts, S. Al-Batran, Pouya Niki	2006	0
18	Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma Journal of Clinical Oncology ·Mathias Rummel, S. Al-Batran, C. Bernius, Manfred Welslau, Emel Bedir, Dorothea Kofahl-Krause, Afina Fahru Miliana, Heinz Dürk, A. Rost, Michael Neise, Ulrich von Grünhagen, Kai Uwe Chow, M. L. Hansmann, Dieter Hoelzer, Paris S. Mitrou	2005	332
19	Kinetics of 5-Aminolevulinic Acid-Induced Fluorescence in Organ Cultures of Bronchial Epithelium and Tumor Respiration ·Fernando Gamarra, Simon D. Wagner, S. Al-Batran, Lee Ji-Hyun, Mirna Castro, Hŭbert Haŭtmann, Albrecht Bergner, Reinhold Baumgartner, Rudolf M. Huber	2002	10
20	Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells British Journal of Haematology ·Robert Dengler, Sayali Nikam, S. Al-Batran, Godwin Joseph Emeka, Stefan Faderl, Christoph Nerl, Bertold Emmerich	1995	85

About S. Al-Batran

S. Al-Batran is a scholar working on Gastroenterology, Pulmonary and Respiratory Medicine, Oncology, Cancer Research and Biotechnology, having authored 40 papers that have together received 1.5k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (21 papers), Colorectal Cancer Treatments and Studies (12 papers), Gastrointestinal Tumor Research and Treatment (8 papers), Lung Cancer Treatments and Mutations (6 papers), Cancer Research and Treatments (5 papers), Cancer, Hypoxia, and Metabolism (4 papers), Cancer Treatment and Pharmacology (4 papers) and Esophageal Cancer Research and Treatment (4 papers). The work is most often cited by research in Gastroenterology (169 citations), Oncology (729 citations), Genetics (262 citations), Pathology and Forensic Medicine (411 citations) and Pulmonary and Respiratory Medicine (680 citations). S. Al-Batran has collaborated with scholars based in Germany, United States and Belgium. Frequent co-authors include Ralf‐Dieter Hofheinz, Florian Lordick, Elke Jäger, Akin Atmaca, Claudia Pauligk, M. L. Hansmann, Dorothea Kofahl-Krause, Heinz Dürk, Michael Neise and A. Rost. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, British Journal of Haematology, European Journal of Cancer and Respiration.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact